Key result
IV istaroxime significantly lowers PCWP by up to ~5 mmHg vs. placebo across all doses.
Why the study?
Istaroxime is a novel intravenous agent with inotropic and lusitropic properties, and its hemodynamic, echocardiographic, and neurohormonal effects in patients hospitalized with HF required evaluation.
Does intravenous istaroxime reduce pulmonary capillary wedge pressure and improve hemodynamic, echocardiographic, and neurohormonal parameters in patients hospitalized with heart failure and reduced systolic function?
RCT (n=120)
3:1
Does intravenous istaroxime reduce pulmonary capillary wedge pressure and improve hemodynamic, echocardiographic, and neurohormonal parameters in patients hospitalized with heart failure and reduced systolic function?
In patients hospitalized with heart failure and reduced systolic function, intravenous istaroxime significantly reduced pulmonary capillary wedge pressure while increasing systolic blood pressure and decreasing heart rate without adversely affecting troponin I or renal function.
Answers are grounded in this paper and cite their sources.
Istaroxime merits phase 2 evaluation in acute HF; leaves open clinical adoption pending randomized safety and efficacy data.
Objectives We examined the hemodynamic, echocardiographic, and neurohormonal effects of intravenous istaroxime in patients hospitalized with heart failure (HF). Background Istaroxime is a novel intravenous agent with inotropic and lusitropic properties related to inhibition of Na/K adenosine triphosphatase (ATPase) and stimulation of sarcoplasmic reticulum calcium ATPase. Methods One hundred twenty patients admitted with HF and reduced systolic function were instrumented with a pulmonary artery catheter within 48 h of admission. Three sequential cohorts of 40 patients each were randomized 3:1 istaroxime:placebo to a continuous 6-h infusion. The first cohort received 0.5 microg/kg/min, the second 1.0 microg/kg/min, and the third 1.5 microg/kg/min istaroxime or placebo. Results All doses of istaroxime lowered pulmonary capillary wedge pressure (PCWP), the primary end point (mean +/- SD: -3.2 +/- 6.8 mm Hg, -3.3 +/- 5.5 mm Hg, and -4.7 +/- 5.9 mm Hg compared with 0.0 +/- 3.6 mm Hg with placebo; p < 0.05 for all doses). Istaroxime significantly decreased heart rate (HR) and increased systolic blood pressure (SBP). Cardiac index increased and left ventricular end-diastolic volume decreased significantly only with 1.5 microg/kg/min. On echocardiography, left ventricular end diastolic volume and deceleration time improved with 1.5 microg/kg/min. There were no changes in neurohormones, renal function, or troponin I. Adverse events were not life threatening and were dose related. Conclusions In patients hospitalized with HF, istaroxime improved PCWP and possibly diastolic function. In contrast to available inotropes, istaroxime increased SBP and decreased HR. (A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function [HORIZON-HF]; NCT00616161).
No takes yet. Share an insight, caveat, or question.
Gheorghiade et al. (2008) conducted an RCT in Heart failure with reduced systolic function (n=120). Istaroxime vs. Placebo was evaluated on Change in pulmonary capillary wedge pressure (PCWP) (p=< 0.05). Intravenous istaroxime lowered pulmonary capillary wedge pressure compared with placebo across all doses.
Synapse has enriched 10 related papers. Consider them for comparative context: